Canada markets open in 37 minutes

Medexus Pharmaceuticals Inc. (MEDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.5400+0.0400 (+2.67%)
At close: 02:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.5000
Open1.5400
BidN/A x N/A
AskN/A x N/A
Day's Range1.5400 - 1.5400
52 Week Range1.4300 - 6.7900
Volume531
Avg. Volume4,537
Market Cap30.727M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

    Management to host conference call at 8:00 AM Eastern Time on Thursday, June 23, 2022TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise. Financial Highlights Delivered total reve

  • GlobeNewswire

    Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

    TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022 to discuss Medexus’s results for its fourth quarter and fiscal year ended March 31, 2022. Medexus expects to file its financial statements and MD&A after markets close on June 22, 2022. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S. caller

  • GlobeNewswire

    Treosulfan Pivotal Study Results Published

    Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm Study results accepted for publication with American Journal of Hematology, now available online Medexus to host webconference with key opinion leader to discuss data on June 6, 2022 at 4:00 PM Eastern Time TORONTO and CHICAGO, June 06, 2022 (GLOBE NEWSWIRE)